7 Biotechnology Stocks to Buy Now

Popular Posts: 6 Biotechnology Stocks to Buy Now5 Oil and Gas Stocks to Buy Now9 Biotechnology Stocks to Sell Now Recent Posts: 10 Best “Strong Buy” Stocks — CSGP TYL PCYC and more 5 Stocks With Bad Earnings Momentum — FNBN NAV SGK LGCY VNR 22 Commercial Banking Stocks to Buy Now View All Posts

This week, seven Biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

Inovio Pharmaceuticals, Inc.’s (AMEX:) grade is moving up to a B (“buy”) this week from last week’s C (“hold”). Inovio Biomedical Corporation is a Delaware corporation, organized in 2001. The Company is engaged in the development of preventive and therapeutic DNA vaccines for cancers and infectious diseases using its novel electroporation DNA delivery technology. Electroporation uses brief, controlled electrical pulses to increase cellular uptake of useful biopharmaceuticals. In Portfolio Grader’s specific subcategory of Sales Growth, INO also gets an A. .

This week, ARIAD Pharmaceuticals, Inc.’s (NASDAQ:) ratings are up from a C last week to a B. ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. .

Neurocrine Biosciences, Inc. (NASDAQ:) improves from a C to a B rating this week. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. .

Array BioPharma (NASDAQ:) earns a B this week, jumping up from last week’s grade of C. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. .

5 Best Blue Chip Stocks To Buy For 2014

This week, Celldex Therapeutics, Inc. (NASDAQ:) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. .

Insmed Incorporated (NASDAQ:) improves from a C to a B rating this week. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. .

This week, BioCryst Pharmaceuticals, Inc. (NASDAQ:) pushes up from a C to a B rating. BioCryst Pharmaceuticals is a biotechnology company that designs, optimizes and develops novel drugs that block key enzymes involved in cancer, viral infections and autoimmune diseases. .

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.